By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use with SomaLogic's Somascan technology platform under a deal announced on Tuesday.

Specifically, Ambergen is licensing its 5-prime photocleavable biotin, a light-activated biomolecule, to SomaLogic. Terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.